Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2021-11-03 00:00:00 ET · period of report 2021-11-01 · accession 0001209191-21-062591 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-11-03 | 2021-11-01 | TEVA | Schultz Kare | Pres, CEO, Dir | M - OptEx | — | +180.0K | 1.04M | +21% | — |
| D | 2021-11-03 | 2021-11-01 | TEVA | Schultz Kare | Pres, CEO, Dir | M - OptEx | $0.00 | -180.0K | 116.4K | -61% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2021-11-01 | M | A | 180,000 | — | 1,040,582 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Derivative | Restricted Share Units | 2021-11-01 | M | D | 180,000 | $0.00 | 116,389 | D | — · — to — | 180,000 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Restricted share units were granted on November 3, 2017, with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. |